EU drug regulator recommended authorizing lenacapavir, a twice-yearly injectable HIV prevention drug Studies suggested lenacapavir was nearly 100% effective in stopping HIV transmission in both sexes Critics raised concerns about Gilead's limited generic availability, excluding parts of Latin America
